Paying users zone. Data is covered by hidden.

  • Get to Allergan PLC for $13.99, or

  • get to whole website for at least 3 months from $49.99.

Microsoft Excel LibreOffice Calc


Common-Size Statement of Financial Position, Liabilities and Stockholders' Equity

Difficulty: Beginner

Allergan PLC, Common-Size Consolidated Statement of Financial Position, Liabilities and Stockholders' Equity

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Accrued third-party rebates hidden hidden hidden hidden hidden
Contractual commitments, including amount due to Teva hidden hidden hidden hidden hidden
Accrued payroll and related benefits hidden hidden hidden hidden hidden
Accrued returns hidden hidden hidden hidden hidden
Interest payable hidden hidden hidden hidden hidden
Royalties payable hidden hidden hidden hidden hidden
Accrued pharmaceutical fees hidden hidden hidden hidden hidden
Accrued R&D expenditures hidden hidden hidden hidden hidden
Accrued severance, retention and other shutdown costs hidden hidden hidden hidden hidden
Litigation-related reserves and legal fees hidden hidden hidden hidden hidden
Accrued non-provision taxes hidden hidden hidden hidden hidden
Current portion of contingent consideration obligations hidden hidden hidden hidden hidden
Accrued selling and marketing expenditures hidden hidden hidden hidden hidden
Dividends payable hidden hidden hidden hidden hidden
Other accrued expenses hidden hidden hidden hidden hidden
Accrued expenses hidden hidden hidden hidden hidden
Accounts payable hidden hidden hidden hidden hidden
Accounts payable and accrued expenses hidden hidden hidden hidden hidden
Income taxes payable hidden hidden hidden hidden hidden
Current portion of long-term debt and capital leases hidden hidden hidden hidden hidden
Deferred revenue hidden hidden hidden hidden hidden
Current liabilities held for sale hidden hidden hidden hidden hidden
Deferred tax liabilities hidden hidden hidden hidden hidden
Current liabilities hidden hidden hidden hidden hidden
Long-term debt and capital leases, excluding current portion hidden hidden hidden hidden hidden
Acquisition related contingent consideration liabilities hidden hidden hidden hidden hidden
Long-term pension and post retirement liability hidden hidden hidden hidden hidden
Legacy Allergan deferred executive compensation hidden hidden hidden hidden hidden
Long-term severance and restructuring liabilities hidden hidden hidden hidden hidden
Deferred revenue hidden hidden hidden hidden hidden
Product warranties hidden hidden hidden hidden hidden
Long-term contractual obligations hidden hidden hidden hidden hidden
Litigation-related reserves hidden hidden hidden hidden hidden
Other long-term liabilities hidden hidden hidden hidden hidden
Other long-term liabilities hidden hidden hidden hidden hidden
Long-term liabilities held for sale hidden hidden hidden hidden hidden
Other taxes payable hidden hidden hidden hidden hidden
Deferred tax liabilities hidden hidden hidden hidden hidden
Non current liabilities hidden hidden hidden hidden hidden
Total liabilities hidden hidden hidden hidden hidden
Preferred shares, $0.0001 par value per share hidden hidden hidden hidden hidden
Ordinary shares; $0.0001 par value per share hidden hidden hidden hidden hidden
Additional paid-in capital hidden hidden hidden hidden hidden
Retained earnings (accumulated deficit) hidden hidden hidden hidden hidden
Accumulated other comprehensive income (loss) hidden hidden hidden hidden hidden
Treasury stock, at cost hidden hidden hidden hidden hidden
Shareholders' equity hidden hidden hidden hidden hidden
Noncontrolling interest hidden hidden hidden hidden hidden
Total equity hidden hidden hidden hidden hidden
Total liabilities and equity hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-24), 10-K (filing date: 2016-02-26), 10-K (filing date: 2015-02-18), 10-K (filing date: 2014-02-25).

Item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Allergan PLC's current liabilities as a percentage of total liabilities and equity declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.
Non current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Allergan PLC's non current liabilities as a percentage of total liabilities and equity declined from 2015 to 2016 and from 2016 to 2017.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Allergan PLC's total liabilities as a percentage of total liabilities and equity declined from 2015 to 2016 and from 2016 to 2017.
Shareholders' equity Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Allergan PLC's shareholders' equity as a percentage of total liabilities and equity increased from 2015 to 2016 and from 2016 to 2017.